Development of Ribityllumazine Analogue as Mucosal-Associated Invariant T Cell Ligands.


Journal

Journal of the American Chemical Society
ISSN: 1520-5126
Titre abrégé: J Am Chem Soc
Pays: United States
ID NLM: 7503056

Informations de publication

Date de publication:
21 Oct 2024
Historique:
medline: 21 10 2024
pubmed: 21 10 2024
entrez: 21 10 2024
Statut: aheadofprint

Résumé

Mucosal-associated invariant T (MAIT) cells are a subset of innate-like T cells abundant in human tissues that play a significant role in defense against bacterial and viral infections and in tissue repair. MAIT cells are activated by recognizing microbial-derived small-molecule ligands presented by the MHC class I related-1 protein. Although several MAIT cell modulators have been identified in the past decade, potent and chemically stable ligands remain limited. Herein, we carried out a structure-activity relationship study of ribityllumazine derivatives and found a chemically stable MAIT cell ligand with a pteridine core and a 2-oxopropyl group as the Lys-reactive group. The ligand showed high potency in a cocultivation assay using model cell lines of antigen-presenting cells and MAIT cells. The X-ray crystallographic analysis revealed the binding mode of the ligand to MR1 and the T cell receptor, indicating that it forms a covalent bond with MR1 via Schiff base formation. Furthermore, we found that the ligand stimulated proliferation of human MAIT cells in human peripheral blood mononuclear cells and showed an adjuvant effect in mice. Our developed ligand is one of the most potent among chemically stable MAIT cell ligands, contributing to accelerating therapeutic applications of MAIT cells.

Identifiants

pubmed: 39432319
doi: 10.1021/jacs.4c12997
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Ryosuke Takasaki (R)

Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Kyoto 606-8501, Japan.

Emi Ito (E)

Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan.
Immunology Frontier Research Center (IFReC), Osaka University, Suita, Osaka 565-0871, Japan.

Masamichi Nagae (M)

Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan.
Immunology Frontier Research Center (IFReC), Osaka University, Suita, Osaka 565-0871, Japan.

Yuki Takahashi (Y)

Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Kyoto 606-8501, Japan.

Takuro Matsuoka (T)

Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Kyoto 606-8501, Japan.

Wakana Yasue (W)

Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Kyoto 606-8501, Japan.

Norihito Arichi (N)

Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Kyoto 606-8501, Japan.

Hiroaki Ohno (H)

Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Kyoto 606-8501, Japan.

Sho Yamasaki (S)

Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan.
Immunology Frontier Research Center (IFReC), Osaka University, Suita, Osaka 565-0871, Japan.

Shinsuke Inuki (S)

Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Kyoto 606-8501, Japan.
Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Tokushima 770-8505, Japan.

Classifications MeSH